Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Clinical trials and evidence)

Innovation 'Elevator Pitch':
Modul-Bio provides a biological data management software specifically designed for biobanks and cohort projects. Main functionalities include patient management, samples collection, processing, distribution and disposal.
Overview of Innovation:
MBioLIMS BioBanking®
 
Modul-Bio solutions allow users to manage the complete lifecycle of biological material and related data. MBioLIMS BioBanking® is dedicated to the management of samples and associated data and is modular and evolutive allowing the expansion and fit of the system to match laboratory requirements..
The whole system is intuitive for end-users, flexible for customization, easily scalable even in a multi-site environment, accepts plug-ins for applications or equipment such as laboratory instruments, robotics or storage, and ensures long term data security.

Access to the application is via a local Browser with no installation required on individual computers. The setup of the system facilitates confidentiality with secured data transmission on HTTPS, and is VPN compatible. MBioLIMS BioBanking® can be installed locally, or as a cloud solution to fit client needs.

It is possible to specify the level of access of each user by creating new profiles with specific roles. It is also possible to show/hide nominative data. Each site can have an internal administrator, trained by Modul-Bio’s team to manage and evolve the solution as required.

A complete Audit Trail is embedded within MBioLIMS BioBanking® which records all actions taken including user registration, who performed the action (create, modify, delete), date and time, fields and values that have been modified. This covers sample movement, transformation to end points such as destruction to provide traceability and information that can be used in reports, audits and business improvement.

Sample storage and movement is fully monitored and storage containers can be designed and edited by system administrators. This allows the client to replicate the laboratory space within the system, monitor and report sample movement and custody. Storage can be assigned to certain studies, or restricted to particular sample types to prevent incorrect use of space. If samples are transferred to other facilities, or external contacts the shipment and manifests of these activities can also be created and controlled within the application. The interface provides a visual representation of the storage system that allows users to navigate all freezers, nitrogen tanks as well as their content all the way to the details of the sample container (tube/plate/2D rack, etc.)

Many other modules are available, and more are developed each year to match biobank requirements.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
MbioLIMS provides a specific solution for biobanking laboratories and projects. This facilitates the management of the patient and sample data, and generates viable sample / metadata for research. It can also be connected to eMBIOBANK, a web catalogue for research use.
NHS data can be stored securely, or held outside of the MbioLIMS application and linked by an anoymous unique identifier. In either case, samples and derivatives are linked to the information required.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Modul-Bio is commited to providing a benefit to all client locations, but has resource locally to the West Midlands.
Current and planned activity: 
MbioLIMS is already used in the UK, with NHS data integration as needed. Modul-Bio is continuing to expand both UK and International clients with the required connection to patient registeries.
The application is designed to improve biobank management, sample custody and viability to promote more utilisation and research for increasing patient well being.
What is the intellectual property status of your innovation?:
The Software and any authorized copy are the intellectual property, the valuable trade secrets and confidential information of the Service Provider who owns the relevant rights. The Software is protected by law, including without limitation the copyright laws of France and other countries, and by international treaty provisions. The Service Provider does not assign any property right when licensing its software solutions and reserves all rights not herein granted. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
MBioLIMS has an available compartmentalisation module which is designed for scalability across regions (or even countries) so that different laboratories can access the same instance when working together.
Modul-Bio has previously implemented solutions within the same regions and once inbedded can facilitate user groups and collaboration.
Measures:
Modul-Bio has designed MBioLIMS to improve biobank processes, sample custody and managment. The system is focused on faster and more thourough management and processing. We do ask current clients for reviews and identified ROI's.
Adoption target:
Target clients are hospitals, universities and private organisations that host a biobank.
 
Read more
Hide details
Mike Woodward 01/07/2019 - 12:27 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Amplitude pro enterprise™ uses simple technology to capture clinical and outcome data for specific diseases, diagnosis, interventions and care pathways. Data is retained locally and available for immediate reporting and analysis.
Overview of Innovation:
The Amplitude pro enterprise™ software is a simple, tailored online platform centred around two crucial elements:
A user-friendly electronic patient portal which gives patients the freedom of completing their scores online at home, on site and via various devices and a consultant dashboard giving the clinician(s) the ability to input patient specific complexity factors and procedure data quickly and easily.

The result is representative, accurate and meaningful data that paints a clearer picture of each patient’s level of health and expected recovery. Clinicians are engaged with the clinical outcomes processes at your hospital, you get the insight required to innovate your clinical services and patients get a consistently high standard of care.

pro enterprise™ is simple, cost effective and delivers precise and accurate data, selecting scores that are identified as important to you.

The data you collect in pro enterprise™ will allow you to monitor your service delivery, identify quality issues and demonstrate levels of care. Your hospital can be confidently transparent about its activities, resulting in reassurance to your peers that you are offering the best care possible.

Amplitude specialises in the collection of electronic PROMs and clinical outcomes and we are the leading supplier of electronic PROMs to the NHS. We are accredited by NHS Digital for the electronic capture and upload of National PROMs and our platforms have achieved the highest levels of IG compliance, using data centres that are ISO27001 certified. 

Amplitude's unique data exchange tool means that you enter and retain your data locally in your pro enterprise™ platform and the necessary data for clinical registries, National PROMs and NJR can be  pushed to the relevant databases on your behalf.

Our systems are designed to empower clinicians in adding value to their data e.g. proper case mix adjustment, log-book, revalidation report and easy analysis and self-monitoring tools. The system automates the process of data collection via a series of reminders sent to patients via email and SMS. These reminders are triggered from the intervention data which at minimum includes procedure/intervention description and diagnosis. 

Amplitude pro enterprise™ is customised and tailored to suit specific department requirements and objectives including virtual clinics, clinical outcomes and PROMs. pro enterprise™ is currently being used in T&O, Rheumatology, Urology, Cardiology and Mental Health departments.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The Amplitude pro enterprise™ system captures and manages clinical and PROM’s outcome data with the key focus to improve overall quality of patient care.
NHS healthcare professionals are required in many specialist areas, to monitor the long-term effects of treatments.  Historically, these were captured on a macro level and this mass gathering of non-specific data, results in outcomes data that is non-meaningful and without sufficient detail or context, preventing its use in making effective, informed clinical and management decisions.
In addition, due to the paper-based nature of how PROM’s and clinical outcomes were historically gathered, often, data would only be made available months after being gathered and in an aggregated and anonymised format, rendering it out of date and of little value.

With Amplitude pro enterprise™, The NHS benefits from the ability to;
  • Capture the clinical outcomes of patients in larger numbers and in an electronic format,
  • Effectively measure the quality of care provided by clinicians in real-time
  • Measure the efficacy of the treatments being used on a local, national and international level
  • Reduce costs associated with carrying out the required questionnaires in a paper format
  • Use the data gathered to compare treatment plans and ensure that patients are receiving the best possible care available
  • Increase clinical and patient compliance and engagement in outcome data collection
  • Meet the challenge to make the NHS paperless
  • Opportunity to provide multiple language options; allowing the patient to complete their electronic questionnaires in their native language instantly
  • Use Amplitude's unique data exchange tool to automatically upload required registry data when the information is gathered in the Amplitude pro registry™ platforms, thus reducing administration, duplication of effort and importantly, retains the outcomes data at the source pro enterprise™ system, allowing instant insight
  • Access to comprehensive reporting tools, that include templated validation reports for individual clinicians, further reducing resource, time and effort
Amplitude pro enterprise™ provides the NHS with a paperless, streamlined data gathering software, that reduces costs, has real-time results, meaningful insights for clinical and managerial decision makers and ultimately improves the overall quality of patient care.
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
The West Midlands AHSN covers 6 regions within the NHS; Birmingham and Solihull, The Black Country, Coventry and Warwickshire, Herefordshire and Worcestershire, Shropshire and Staffordshire.

Within this area, there are 33 NHS Trusts servicing the needs of a population of approximately 7.225 million (ONS 2017). According to the ONS, 18.2% of the population were aged 65 years and over.
It is also documented that over half (54%) of older people have at least two chronic conditions increasing to 69% among those aged 85+ (Kingston, et al., 2018).
Multi-morbidity increases the likelihood of hospital admission, length of stay and likelihood of readmission, raises healthcare costs, reduces quality of life, and  increases dependency. (Kingston et al., 2018).

These are all operational factors being faced in the West Midlands region and the implementation of innovative technologies, to help manage the growing dependency on the NHS, are essential.
The implementation of Amplitude pro enterprise™ will not only allow for monitoring outcomes, it can also use the outcomes data to manage workloads, triage clinics and help to influence operational management. 

Eg; fracture clinics see all patients admitted to A&E with musculoskeletal problems, the system could reduce the number of follow up appointments in Trauma and Orthopaedics clinics by assessing cases in a virtual clinic, prioritising the appointments of patients that require surgery or a clinic appointment and booking those that are less urgent into follow up clinics.

Or: The Amplitude pro enterprise™ platform can provide the method of prioritising more urgent cases in Rheumatology or Cardiology clinics, allowing urgent cases to be seen ahead of patients who are performing well with their current ongoing treatment plan.

Managing the patients according to need and not by pre-set time frames, could help to prevent potential A&E visits by patients who deteriorate or do not respond as expected to their treatment plans.

Administrative workloads can be reduced, and the overall quality of care provided to patients can be dramatically improved, whilst overall cost savings are obtained as a result.

In addition, administrative productivity can be increased with the data exchange tool. For mandated registry data submission such as National PROMs, NJR and now BSR (Apr 2019), data is entered just once and the Amplitude pro enterprise™ platform uploads the relevant information as required, with the data being retained for local analysis.
Current and planned activity: 
With a wealth of NHS experience in the Amplitude team, the products we design and develop have NHS priorities and needs at the heart. When the pro enterprise™ platform is deployed into a hospital or trust, the Amplitude development team continue to improve the system to best service it’s users. Upgrades are released annually, upgrading the functionality on a regular basis.

CCG’s are looking at commissioning based on outcomes and lucrative contracts are sent to the trusts and hospitals with the best results. pro enterprise™ ensures boards can evidence their results to win these contracts, adding funding to budgets.

pro enterprise ™ promotes interoperability. The ability to receive data via exchange from a growing number of PAS’s is a major factor in reducing administrative workload and costs, but when this technology is combined with the ability to also push the data (electronically) to populate the associated registries too, the benefits and cost reductions are multiplied.
What is the intellectual property status of your innovation?:
Amplitude Clinical Outcomes own the intellectual property rights on this platform.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sarah Steptoe 16/04/2019 - 10:58 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Hospify is a health data platform built on free & trusted messaging for patients and clinicians. A free messaging app is available to all users; a team messaging platform is sold to hospitals, surgeries, pharmacos and other healthcare institutions.
Overview of Innovation:
  • Hospify is an ubiquitous health comms ecosystem that puts patients & clinicians in control of their health interactions in a way that everyone can access and trust
  • Hospify allows patients to connect with and control their communications with healthcare providers, pharmacists, pharmacos and insurers
  • Like Slack in the commercial sector, Hospify uses open standards to enables other health apps and digital services to function within an ecosystem that benefits all parties involved
  • Hospify’s unique “serverless” phone- powered network architecture allows it to scale users without scaling costs while staying compliant with all data regulations.
     
There are lots of healthcare messaging companies popping up. So what makes Hospify different?

1) A messaging platform is only useful if everyone can be on it. That’s why people love WhatsApp. For everyone to be on it, the core platform has to be free. Hospify is built on a unique serverless architecture that allows it to scale the app without scaling the costs of supporting it.  This allows Hospify to offer its core messaging, for free, to everyone, forever, without needing to monetize our users’ data or sell them ads in order to do it. 
2) That serverless structure means that we don’t store users’ data (one of the reasons that we can’t monetize it!). All the data, at least in the free, secure and compliant app, is kept on the user’s device, and only on the user’s device. This means that compliance is baked in from the start, and enormously reduces data liabilities and security overheads - which in turn helps support our ability to provide the app for free to the majority of users.
3) Hospify is really simple to use. Most of our competitors are building complicated messaging tools designed to appeal to doctors. But at Hospify our focus is on nurses and patients - the people at the sharp end of health, who want solutions that are simple and effective and don’t require a manual in order to them figure out.
4) The Hospify messaging app is only part of what we do. Hospify’s secret weapon is the HospifyHub. The Hub transforms the App’s “WhatsApp”- style experience into something that’s more like Slack, with a web portal and a desktop app that syncs with users’ phones without compromising our compliant and scalable “serverless” architecture. The Hub offers administrated groups, broadcast messaging, and data capture via messaging surveys, and is designed to integrate with and handle data from third-party apps.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Efficiency gains from simple, non-siloed comms
Reduced risk of data breach and better clinician & patient privacy
Reduced time to decisions
Fewer face-to-face follow-ups
More timely interventions
Improved patient-centric care  
Improved mobile working
Improved interdisciplinary and inter-organisational working
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
Easier access to clinical professionals
Reduced travelling to appointments
More control over personal health data
Reduced risk of health data breach
Less frustrated clinical staff!
Reduced spend at CCG level on SMS
Current and planned activity: 
Traction (App)
  • Hospify’s free messaging app is live in the Apple & Google app stores with more than 4000 sign-ups across 60 hospitals since launch in Feb ’18 and 25% monthly active users.
The Hospify App is secure and compliant for health use across the UK and EU. End users can download the FREE Hospify App via the Apple and Android app stores.  

Live Trials (Hub)
  • Unison Health: paid trial at University Hospitals North Midlands. Intention to scale out nationally to >1k branches and >500k nurses
  • Birmingham Community NHS Trust: free trial
  • Cambridge & Peterborough NHS Trust: free trial
  • Lincolnshire Community NHS Trust: free trial
  • Medway Community NHS Trust: Up to 900 users for 3 months’ free trial
  • Corby NHS Health Centre (Lakeside+): 90 users for 3 months’ free trial The GP Service: telehealth company with national reach
 
 
What is the intellectual property status of your innovation?:
UK trademarks filed; EU, Colombia & US trademarks in process.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regulatory Approvals:
When designing its message delivery and information security architecture in 2015, Hospify carried out detailed discussions with the Information Commissioner’s Office about the legislative landscape around secure messaging in health. As a result, Hospify combines cutting edge technology and powerful security with careful consideration of UK and EU rules for handling patient information, and has the following accreditations:
  • GDPR & 2018 UK DPA compliant
  • NHS IG Toolkit (2017-2018) & DSPT (2019) (Org code: 8JN92)
  • Crown Commercial Service supplier (GCloud 11)
  • ISO 27001:2017 accreditation (Registration number: 214722)
  • ICO registered (ZA239336)
  • US encryption export registered (SNAP-R ERN R11191)
 
Read more
Hide details
James Flint 11/03/2019 - 14:39 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ISL has recently developed a Clinical Trial platform that could be used for collaboration by multiple institutions including NHS/Academia/Pharma/Industry.  Shared protocols, intelligent workflows and secure data management underpin the solution.
Overview of Innovation:
Ensuring your data is accurate, your samples are viable and your results are verifiable are essential when managing clinical trials and carrying out research.

Achiever Medical provides your laboratory with the functionality to manage data quality and integrity, an audit trail to help you assess the quality of your samples and a workflow tool to help map your processes into the solution, including managing the approvals process.

  • Clinical trial functionality to allow easy adoption and customisation for launching and building up clinical trial datasets
  • Manage cohorts, studies, samples, visits and results within a single system that can be shared amongst all collaborating parties
  • One system across multiple institutes, pharma, industry and academia
  • Management reporting cross centre
  • Create and deliver trials quickly with customised data requirements
  • Enforce trial protocols to promote quality and single approach
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
  • Rapid rollout of system to support data capture of clinical trials
  • Modify processes and protocols per clinical trial with minimal recourse to IT
  • Share data regionally/nationally across trials
  • Role based permissions to protect data
  • Single system to administer
  • Adapt processes and protocols for trials quickly
Assess Sample Viability
Ensuring you are carrying out research on viable samples is essential when validating any results.  Achiever provides a comprehensive audit trail against each sample including complete details of storage location history (with a temperature audit),  sample check out history (when, by whom, how long and for what purpose) and sample processing history (with sample collection date/time, processed date/time).  A complete sample family history is also available for managing aliquots with related samples (including parent) accessible with a single click.
 
Maintaining Confidentiality
Confidentiality is not only critical when handling patient information but is also a legal requirement.  Achiever offers flexible, secure data protection options to restrict access to identifiable and sensitive information to authorised users only.  Data encryption routines encrypt data at source whilst data security filters only allow authorised users access to selected information within the system.
 
Managing Studies and Workloads
Define studies within the Achiever system and link team members along with their relevant roles.  Generate activities to create and manage workloads with a graphical calendar available to view team schedules.  Monitor and track equipment and consumables used. Capture analyses and results along with any associated documentation and images.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
  • Make clinical trials available quickly to patients within the WM region
  • Ease of reporting to present efficacy of trial within the region
  • Show proactivity of centres and success in recruiting potential volunteers for trial
Current and planned activity: 
The functionality is being rolled out within a Health Trust in the East of England.  The company now wishes to find a national / regional opportunity that would benefit from a single system to promote trials.
What is the intellectual property status of your innovation?:
Released.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
Sandie Shokar 30/08/2018 - 16:55 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
QxMD is a company dedicated to creating point-of-care applications created by for healthcare professionals, with a global community of 1.9 million clinicians, medical students, scientists and researchers and are free to download and use at any time. 
Overview of Innovation:
Healthcare professionals need to stay up to date on the latest medical research and topic reviews to provide optimal care. Unfortunately, the process of content discovery is broken with research artificially compartmentalised by publishers and hidden behind countless institutional paywalls.

At QxMD, we believe that knowledge translation– the process by which new knowledge is incorporated into clinical practice – is an important and unsolved challenge for our health care system. Read uses smart algorithms to ensure that each and every user has a dedicated newsfeed of research that applies to their practice. 
With Read, Institutional Edition, organisations can seamlessly integrate their existing journal subscriptions and existing proxy service to provide a platform for their clinical staff to access content which matters to their individual practices. It is built with features designed to improve patient care and reduce costs. 

The Promoted Research feature is used by institutions who want to disseminate research that impacts areas of care the most within their organisation. For example, a Hospital with high rates of Sepsis can use this tool to promote guidelines that reduce Sepsis cases with higher guarantees their clinical staff will discover the research and apply it to the next patient. 

Librarians and Knowledge Managers can take advantage of smart analytics to understand which journal subscriptions are performing the best and worst and also which journals are most popular, which they don't subscribe to.

NHS Trusts are already adopting QxMD, with over 100,000 users in the UK alone. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
  • Better educatad and up-to-date staff, specific to their practice
  • Cost saving on journal subscription costs
  • Improved patient care
  • Challenges identified and tackled via the Promoted Research feature
  • Easy to discover and access research from any smart device
  • Links with OpenAthens for instant access to subscribed content. 
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
  • Better educated healthcare professionals who can identify the latest research and apply it to patient care
  • Less chances of mis/under diagnosis, readmission or even death
  • Improved quality of care
Current and planned activity: 
  • Existing NHS Trust clients, including the largest Mental Health Trust in the UK
  • Continue to grow our userbase, which is already at 100,000 UK users, with the support of Trusts and other stakeholders. 
What is the intellectual property status of your innovation?:
  • We have designed and developed the platform entirely in-house. No white-labelling. A completely unique tool built by Healthcare Professionals for Healthcare Professionals. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Jimmy Connoley 19/06/2018 - 12:56 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Currently, a GP refers Obstructive Sleep Apnoea patients to an NHS Specialised Sleep Centre. Averaging 24 wks & 3-5 hospital visits before the Patient starts treatment.
Now, a GP with SOMNOtouch can receive results in 48-72Hours (3days vs. 6Mths)
Overview of Innovation:
Currently
The vast majority of patients with Obstructive Sleep Apnoea (OSA) are referred by their GP to a Specialised Sleep Centre at an NHS Hospital with a Average waiting time 12 Weeks


Patients are initially seen by a Consultant or a Sleep Physiologist who would prescribe a Diagnostic Study to be performed either in hospital or at the patient’s home. Average waiting time 12 Weeks
The patient returns to have the sleep study done or to collect the monitor and then returns the device the next day. After a further waiting time of upto 6 Weeks the patient visits the hospital again to obtain the results of the sleep study and if Positive, to discuss treatment.
A letter is sent to the GP informing them of the results and if agreed, a prescription is issued by the GP for the recommended therapy this may also take an average of 6 Weeks to arrive.
 This is prior to any treatment being administered such as a CPAP where if used they attend annually to check on compliance and progress.
 
This 6 month process is dramatically reduced by the S-Med Service to just a few days before an intervention can be delivered.


Now
The GP fits SOMNOtouch, a Combined OSA/Hypertension Monitoring Device to the patient, after 24 hours they return to the GP practice where the device is removed and the GP uploads the data from the device to a secure NHS Digital Cloud Server.
SOMNOtouch NIBP - Five devices in One
Video link: http://www.s-med.co.uk/Products#nav-product-86
 
S-Med Ltd’s Qualified and Registered Physiologists interprets the study and provides a recommendation for further treatment or investigation within 24 to 48 hours to the GP surgery. (All analysis and interpretations are supervised by a senior Consultant).
 
The report is sent to the GP who would then provide a prescription for the relevant therapy to be provided.
 
Thus within 48 to 72 hours a patient can be treated or directed for additional investigations or treatment before their condition deteriorates.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Faster response times and time to providing treatment from an average time from referral to treatment of 6 months (24 weeks) down to 4 to 5 days (1 week). With the added benefit if there are more critical underlying conditions then these may be picked up and dealt with quickly
 
Reduction in costs of patients being referred to NHS sleep centres thus less calls and pressure on such specialist clinics e.g.:
 
Reimbursement Tariffs for OSA and Hypertension
Current reimbursement guidelines from the Department of Health are:
  • For Ambulatory Sleep Diagnostic Study: £391.00
  • For 24-Hour NIBP Study: £268.00 (UCL NHS Foundation Trust, there is no NHS tariff)
  • For 24-Hour ECG Study: Recording - £268.00 plus Analysis £215.00 (UCL NHS Foundation Trust, there is no NHS tariff)
 
Cost Savings Calculation
Assuming the following:
  1. Adult Population of the England is Approx. 45 million
  2. BLF figure show approx. 10% of population suffers from OSA = 4.5 million
  3. DH figures show that approx. 30% of adult population has Hypertension = 13.5 million
  4. Public Health England shows that 1.3 million people have Atrial Fibrillation
 
The cost of referring 1% of the above population to hospital annually, will cost approximately:
  1. OSA – 45,000 £32 million per year.
  2. Hypertension – 135,000 £79 million per year
  3. AF – 13,000 £10.5 million per year
 
Total cost of £121.5 million
Cost of S-Med Service - £38.6 million
Savings to NHS = £83 million per year.
 
Aside from OSA, this equipment can be used for chronic heart conditions studies as well as more longitudinal studies adding a wealth of data for clinicians to inform them of patient’s conditions at work, rest and play without the equipment being intrusive and disturbing as current cuff based systems thereby removing the abnormal results they can provide. Thus, this equipment may also be of benefit to clinical trial units or during treatment to monitor the physiological effects experienced by patients undergoing a drug or other clinical interventions. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
In addition to patients getting a faster diagnosis, it will reduce the burdens on NHS Trusts not only from the reduction on 1st line referrals to hospitals, but from patients conditions deteriorating, or suffering economic or social problems waiting 6 months for a diagnosis and treatment to be considered.

North West Innovation Agency (AHSN) will be conducting a pilot which will monitor 75 patients via a number of GP’s Practices. Results should be available by the End of February 2018.
As a West Midlands based company we would welcome an opportunity to work with NHS Trusts and CCG’s within the region to help us grow this service within the UK for the NHS and to increase our team to service and facilitate such requirements.  
Current and planned activity: 
Current NHS engagement
  • Embarking on a NIA application with North West Innovation Agency
  • Submitted an application into the ITP based on experience and adoption within the NWIA area.
  • Considering a NIHR project following a meeting at AHSN meeting - Speaking with West Midlands NIHR/CRN
Requested NHS engagement
  • Procurement / Adoption of: -  Would welcome assistance to gain greater Adoption by Trusts and CCGs within the West Midlands
     
  • Evaluation / Validation / Clinical Trial – Interested in trials for use of our ambulatory equipment (SOMNOtouch) within new clinical areas to show its versatility and extend its clinical use to provide validated evidence within in these new areas.
     
  • Project Assistance S-Med is interested in locating potential clinical / academic collaborators to engage in their current work and to explore other clinical applications of their technology.
What is the intellectual property status of your innovation?:
Device IP held by SOMNOmedics Germany. Clinical diagnostic and reporting service is owned by S-Med Ltd.
Reg. CE0494
We have obtained IGSoC Level 2 (ODS Code: 8JP12)
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Read more
Hide details
Selwyn Sher 03/10/2017 - 13:27 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Achiever Medical LIMS helps research institutions to improve lab efficiency, facilitates return on investment into sample collections & demonstrates compliance to legislation. Inbuilt security protects patient identifiable data with controlled access
Overview of Innovation:
With increasingly stringent regulations and greater emphasis on profitability placed on laboratories, Achiever Medical LIMS was designed in conjunction with leading scientists & clinicians to provide an easy-to-use sample management system incorporating sample tracking, clinical data management, workload & communication management. The system addresses the gap left by traditional LIMS systems by providing enhanced donor and research profile data.
 
Achiever Medical LIMS is a process driven & web browser-based laboratory & clinical data management system that is flexible/scalable to evolve as needs develop. Using Open Standards to streamline the sharing of information across existing applications Achiever Medical LIMS allows data to be imported from, e.g. Patient Information & Storage Environment Management Systems, Lab equipment, Emails & Calendars for an holistic overview of samples, equipment, environment & workload.
 
Achiever Medical LIMS enables the mapping of Standard Operating Procedures (SOP) to ensure staff adhere to agreed standards, ensuring regulatory compliance & promoting quality, efficiency & consistency. Achiever Medical LIMS can assist in compliance with the Human Tissue Act, Good Laboratory Practice & CFR 21 Part 11.
 
Sample tracking functionality delivers complete traceability with automatic generation of unique reference numbers for each sample. Core sample details e.g. location/sample type are tracked as values change for a complete audit history. Sample profile information is captured including sample & tissue type, tissue collection details and associated patient & project information. Barcode labels can be generated for single/multiple samples & customised information can be contained within each label. These labels can be scanned to facilitate rapid sample retrieval.
 
Achiever Medical LIMS integrates data and processes across multiple faculties/diverse into a single solution. This enables authorised users to gain an holistic oversight, having full access to complete donor/patient records. Robust security filters and flexible tools within the LIMS allow the creation of custom levels of user security access to samples, donors or project information. This flexibility is especially useful for biobank or bio-repository management or when conducting multiple studies/clinical trials/projects with multiple collaborators. These tools support collaborative working and simplify a task that can otherwise be legislatively difficult and time-consuming.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health
Benefit to NHS:
Achiever’s LIMS ability to quickly and efficiently organise samples for tracking, storage and retrieval, enables the full economic and scientific value of existing samples to be effectively realised and more efficient processing of sample requests and tests.
 
Achiever Medical LIMS enables sample aliquots to be easily generated from the parent record for complete traceability with a sample ‘family history’ view available, from both the parent & child records, allowing rapid navigation between samples within the same family.
 
Tools to enable the detailed tracking & monitoring of a sample via comprehensive sample location & check in/out auditing are provided. These include recording each time the sample is removed from its location, who checked it out and for what purpose. Samples that have been ‘checked out’ are easily identifiable and can be quickly ‘checked in’ when required along with their full audit trail information.
 
Samples used and associated stock depletion during testing or analyses are automatically flagged with Achiever Medical LIMS.
 
Composite samples such as Tissue Microarrays can be easily created within Achiever Medical LIMS, with each individual sample’s position within the composite sample recorded, any requests for removal can be easily and effectively managed.
 
External sample requests received by biobanks & bio-repositories can be managed through Achiever Medical LIMS using its built in management protocols. This facility provides staff with complete chain of custody details for each sample ((the person who requested the sample, reason for request, who approved the request & expected return date (if required) are captured)). Rejected requests are appropriately managed with reasons for rejection being recorded. Where only part of the sample is required, aliquots can be generated for the required amount along with accompanying complete family history record. Dashboards highlight samples due for return, allowing staff to monitor/chase up samples where required.
 
Achiever’s complete sample auditing & sample tracking functionality records changes by staff to core sample information. Audit trail information includes details of specific information fields changed, values pre & post change, date, time and name of the user who made the change etc. Chain of Custody details, including who checked in the sample, to whom it is checked out (where relevant), storage location, details of processing and projects included in are also captured.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The West Midlands population has access to the most extensive range of specialist tests from a range of stakeholders, showcasing the potential of laboratory contributions to raise the profile of the research, clinical and diagnostic expertise of the region’s NHS laboratory staff.
 
For laboratories, biobanks and bio-repositories sample tracking & donor management capabilities are of huge importance in donor profiling, consent management, traceability, chain of custody & regulatory compliance.
 
The integration of a potentially region-wide system to manage tissue tracking across multiple teams, hospitals and sites can avoid duplication of data entry and maximise data quality while working within the IT and legislative constraints imposed by disparate working environments of the users.
 
Having sought approval for sample collection, samples need to be treated in line with SOPs and available for use in research both internally and with permitted collaborators.  Utilisation of samples is important to maximise the potential benefit from the donor and to make best use of the resources available to clinicians and researchers.  Cost recovery models allow for income generation to promote the sustainability of the biobank.
 
Improving the value of data quality enables laboratory staff and researchers to search for tissue samples from specific cohorts of donors, filtering by level of consent given by donors, allowing them to search for tissues that have not opted out of specific elements of research. This level of capability will allow biobanks and bio-repositories to service very specialist research requests, increasing value.
 
The quality of the donor, consent, storage and tissue viability data greatly increases the value of the tissues to laboratory staff and researchers. Once cleansed, Achiever Medical LIMS’s storage management capabilities help to increase levels of utilisation, reducing overhead costs per sample.
 
The ‘Achiever Medical Researcher Portal’ allows authorised collaborators to view restricted data for relevant samples.  This external view portal promotes the management of sample requests all within a single system, giving an easy means of sharing samples and the relevant data.  Automatic alerts ensure applications are managed efficiently.
 
In addition, reports and analysis providing real-time data, can be run at the touch of a button instead of valuable laboratory personnel spending days (sometimes weeks) painstakingly collating information from various spreadsheets.
Current and planned activity: 
We are a West Midlands based company wishing to work with our regional health providers.  
 
Our current users include Leeds (LTHT), Nottingham (NUH) and Cambridge (CUH) Trusts all of whom use the system to manage their research samples, donor data and to support HTA Audits.
 
Both NUH and CUH use Achiever Medical as part of their involvement with GEL.
 
Achiever Medical is being used to pioneer the data standards being promoted by UKCRC.
 
We would like to work with WMAHSN who are leading the collaboration of The West Midlands Genomic Medicine Centre (WMGMC), a partnership of 18 NHS Acute Trusts across the region, working collaboratively to help to deliver the UK 100,000 Genomes Project.   
We would welcome the opportunity to discuss any requirements for sample management and donor management, projects and disease specific systems for either single organisations or multi-institutional requirements.
What is the intellectual property status of your innovation?:
All IP is owned by Interactive Software Limited.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sandie Shokar 01/08/2017 - 09:19 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
MIRA is a software application designed to make physiotherapy fun and convenient for patients in need of rehabilitation. It turns physical exercises into video-games and uses Microsoft Kinect to track and assess patient treatment compliance.
 
Overview of Innovation:
Physiotherapy and rehabilitation can be a long, difficult and sometimes painful process. Treatment plans can be cumbersome and a slow recovery can be disempowering for patients. 70% of patients do not adhere to home exercises, which increases the total time needed for recovery, leading to higher costs for the healthcare sector.

MIRA displays these exercises as video-games and asks patients to complete the recommended movements to progress through each game level. As a result, patients are playing, while at the same time actually recovering. The patient’s performance data is also tracked, storing all the repetitions, improvements or issues for the therapists to adapt the treatment accordingly. As each patient and their treatment require careful planning, MIRA is designed as a tool for the therapists, to enable specialists to customise the treatment for each individual. Our innovative software can be tailored to the patient’s condition, needs and goals (stroke, falls prevention, MSK disorders etc.), using off-the shelf hardware (laptop/PC and motion sensor).

The software application is registered as a Class I Medical Device in Europe (CE Mark) and can be installed in any clinical environments where patients go for their regular treatment sessions, as well as at home where patients can be remotely monitored by their therapists. This allows the patient to exercises at home under the remote supervision of a healthcare provider. Furthermore, MIRA reduces costs by supplementing staff and reducing waiting times, as well as by decreasing the necessary number of clinic visits and the travel costs associated to them.

The system runs on Windows PCs, using Microsoft Kinect, a mainstream motion capture camera, to engage and track patients throughout their treatment.

MIRA Rehab has 14 UK institutions and another 44 worldwide, helping 600 patients monthly.  The youngest patient to have ever used the system was 3 years old, while the oldest is 102. MIRA was recently featured on BBC, as well as on TED.com in 2015.












www.mirarehab.com

Video links:
MIRA – Play your way to recovery
MIRA – Helping older people regain their mobility
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Person centred care
Benefit to NHS:
The primary benefits to NHS provided by using MIRA are mostly related to health outcomes, efficiency & cost effectiveness. Thus, MIRA can:
  • Supplement staff shortage and reduce waiting times, by enabling more patients to be treated at the same time at the clinic as well as remotely supervised at home
  • Reduce recovery time for a large group of patients by increasing motivation for the adherence to treatment through an interactive and engaging exergaming tool
  • Reduce costs associated to travel by decreasing the necessary number of visits to the clinic
  • Prevent further injury or surgery and thus reduce important costs associated to further hospitalisations and treatment caused by lack of compliance to the initial treatment
 
Quotes from NHS clients
"The [MIRA] concept is that it will replace me, as the clinician, or the therapist who is going to do the exercises with the patient. Not for all of the time, but for a part of the time. So it will supplement what we do and it will also improve patient care because patients will do it better based on the principles of gamification. When I describe it to people, people just go Wow! If this continues, it will change the way modern medicine is practiced"
Mr Bibhas Roy,
Shoulder and Elbow Surgeon, Central Manchester NHS Foundation Trust 
               
“There is huge potential. I give a lot of talks to older people and they are very interested…There is a great need there. You can have a lot of patients using the exergames at home with the physio reviewing and keeping an eye. With the data that is remotely sent to the clinic you can very easily see if individuals are complying, improving, and if they are not improving whether they need a visit.
Emma Stanmore,
Lecturer in Nursing, The University of Manchester
 
“Many individuals over the age of 65 haven’t played computer games before, but those who have been helping us test the technology have given us very positive feedback.”
Emma Stanmore,
Lecturer in Nursing, The University of Manchester
 
 “MIRA is an innovative product that could alter the way therapy is delivered to patients in the future. It has the potential for patients to be more active in their rehabilitation, which should result in improved patient and service outcomes.”
Mark McGlinchey,
Clinical Specialist Physiotherapist, Guy’s & St. Thomas’ NHS Foundation Trust
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Benefits for WM
  • An innovative tool that offers the possibility to have a better supervision of their patients, better medical outcomes and a more competitive practice
  • Created based on the best available clinical evidence (ex. Falls prevention exercise package) and validated in clinical trials
  • Net average saving associated with the use of Exergames for falls prevention would be £1,202 per patient per year for one MIRA unit (Health Economic Report by JB Medical)
  • The clinic can offer MIRA as a separate therapy service, developing a new business opportunity, improving treatment and physiotherapy services delivery (like reducing waiting times)
  • MIRA allows them to track patients’ compliance and progress at home
  • Reduce readmission and costs associated to further treatment and hospitalisation due to non-adherence to initial prescribed therapy (ex. Home exercises are more likely to be done if patients are being checked and if they have an engaging tool.
  • Specific therapy plans for patients can be prescribed from any location, and  it offers a suit of customisable exercises and games that therapist can easily tailor as they see fit for their patients
  • Possibility to monitor and engage more patients at the same time
  • Based on this modern instrument with its data gathering feature, therapists can access new research opportunities, important movement data and statistics that were not easily available before
  • Patient data is safe – data protection and security regulations have been carefully implemented to ensure best protection and security measures required have been implemented
Benefits for its population
  • An attractive environment through gamification engages patients to perform the prescribed exercises and comply with their treatment avoiding further complications and reducing recovery time
  • A new, easy and fun way to interact with rehabilitation or therapy
  • Patients can continue exercising in between clinic sessions being guided and supervised by a medical specialist, keeping a closer contact with the clinicians
  • Based on occupational therapy MIRA distracts the patients’ suffering and focus on pain while exercising
  • Increase the quality of patients’ life and of their families
  • When they cannot attend the therapy sessions MIRA is an efficient tool and fast way to perform the prescribed treatment plans at home
Current and planned activity: 
Current NHS Engagement:
1. Central Manchester University Hospitals NHS Foundation Trust (CMFT)
2. Guy's and St. Thomas' NHS Foundation Trust (GSTT)
3. Epsom and St Helier University Hospitals NHS Trust (ESTH)
 
Planned Activities/Upcoming:
Five other NHS organisations are in the process of implementing MIRA in their treatment delivery;

MIRA is a platform created to support extensions with new packages targeting new types of rehabilitation (hand fine movements, aerobics, speech therapy, etc.). Thus, we are willing to engage with clinical partners for clinical input, studies and validation on the development of the new modules. 

(See attached NHS Engagement document for further details)
 
What is the intellectual property status of your innovation?:
No patent on product as it is a software product (trade secret). We have full copyright of the software and source code of the application.

We are in the process of registering the MIRA trademark.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Read more
Hide details
Cosmin Mihaiu 11/04/2017 - 16:53 Publish Login or Register to post comments
6
4
Votes
-99999
Innovation 'Elevator Pitch':
Monsenso is an innovation leader within mHealth for mental health, providing a Class 1 CE-marked medical application for data collection and sharing, to support better mental health at lower costs.
Overview of Innovation:
Monsenso is a solution that enables easy development and deployment of user-centred monitoring and feedback systems, which are tailored to a specific mental health problem, such as bipolar disorder. The system is configurable, which enables accommodation of clinical needs and easy implementation within clinical settings. The core of the system is to support a continuous monitoring and feedback loop that allow data to be sensed and entered by the individual, while the system then use this collected data to provide appropriate and situated feedback to the individual, as well as sharing data with a care provider and, if appropriate, a caregiver.


As illustrated in above figure, the Monsenso Solution provides individuals with a smartphone application, on which they perform daily self-assessments. Furthermore, the individual's’ physical condition can be monitored automatically through the embedded sensors in the smartphone. The system can detect behavioural changes through configured triggers and early warning signs to give individuals useful feedback.Furthermore, the app provides the individual with action plans for tackling certain situations that they might encounter.
All this information is visualised for the individual through graphs, and simultaneously synchronised in real time to a web portal for care providers, giving them the needed overview and information about their assigned individuals’ mental health. This way the care provider can channel efforts towards individuals who really need help and physical consultations. When the individual then comes in for a consultation, the care provider has a broad historical overview of the individual’s mental health over the past period, instead of relying on the individual to share this information.
 
The Monsenso Solution allows individuals to grant access to caregivers, to receive aggregated data regarding the individual through the app. This keeps caregivers informed remotely of the wellbeing of the individual, and enables them to provide input for both individuals and care providers. Not only does the solution keep the caregiver informed about the state of the individual, it also helps the caregiver cope in situations that might arise. 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details
Drew MacKenzie 29/03/2017 - 12:00 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
SMC provides an innovative, integrated, digital platform solution that deliver better patient outcomes, greater self-management and delivers healthcare more efficiently. The system is highly configurable and customisable and deployable at scale.
Overview of Innovation:
SPS have created an open, future proofed digital platform that harnesses and integrates a range of mobile, communication and wearable technologies to pre-emptively and pro-actively support improved patient outcomes while enabling more efficient healthcare service delivery across primary, secondary and social care environments.
Our mobile health (mHealth), telemedicine and telecoaching solutions use familiar mobile and ‘cloud’ based technology. It has been proven to  support service redesign and deliver more efficient, patient centric healthcare that’s cost effective, simple to use and easy to implement at scale.
Our ‘open’ architecture and web based platform enables more holistic Long Term Condition management services by leveraging a range of technologies across mobile, tablet, text, video and voice to deliver a highly flexible solution for healthcare professionals and patients. Mobile health (mHealth) enhances patient outcomes by enabling clinicians to pro-actively and pre-emptively monitor patients remotely while also enabling the individual to better understand and manage their condition that results in improved patient outcomes, reduced visits to hospital and local GP’s Surgeries.
Our SMCTM solution can be customised to meet any Long Term Condition (LTC), co-morbidity or medical condition that an individual may suffer from. It can support one or multiple LTCs, as well as any other health or mental health condition where a question or vital sign measurement can be of benefit. To date core commissioning has been focused on supporting people who suffer from Heart Failure, Coronary Heart Disease, Hypertension, Chronic Obstructive Pulmonary Disease, Asthma and Diabetes, but we have also developed profiles to support Urinary Tract Infection, Falls Prevention, Dementia and Depression management, Cystic Fibrosis, Obesity and end of Life.
The SMCTM solution is deployed across multiple CCG’s and provider in the UK with over 10,000 patients benefiting from the system over the past 5 years. We have supported different operational and clinical pathways, including effective system deployment into patient homes and Care Home environments that can then enable pro-active and pre-emptive alerts to be raised with a Clinical care team.  Our technology and services have also been selected by a wide range of organisations including BT Health, Alere, Welch Allyn, MSD Commercial, Healthcare @Home to support new and existing service models in the field of telehealth.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Key deliverables achieved with SMCTM solution:
  • Facilitate early patient discharge and reduce bed days: Harrow CCG, 2014: achieved a 50% reduction in unplanned admissions and 63% bed day reduction to deliver an ROI of 159% and net savings of £3,444 per COPD and cardiac patients.
  • Improve prevention and early intervention:  Derbyshire Community Hospital, 2014: achieved a 68% reduction in unplanned admissions; 415 bed day reduction across 187 patients in a 6 month period with a net saving of c£100,000.
  • Improve service value and efficiency of service provider: Bristol CCG, 2013: within just 30days of the telehealth service starting the number of contacts reduced by 26% with an 18% reduction in face to face time and 40% reduction in telephone contacts
  • Sustain independent living and improve patient outcomes: Birmingham Community Health, 2014: Surveyed 312 patients with 86% of patients stating system helped them manage their condition; 84% more involved in their care; 90% happy to reduce the number of routine hospital visits.
     
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
SMC offers multiple benefits for patients:
  • Personalised care modules: supports an individual's care needs using the most relevant questionnaires, vital signs and content.
  • Embedded educational content: on demand video aids training, behaviour change, understanding and the confidence for patients to self-manage their condition.
  • Sustains independent living: the use of relevant, integrated and familiar technology empowers patients to better understand and manage their conditions at home.
  • Easy to use and "out of the box": use fo familiar smartphones and tablets with wireless peripherals; audio and multi-lingual options.
  • Remote access and support software: touchscreeen enabled device support over the phone.
  • Video tele-consultation: remote "face to face" clinical consultation to aid better clinical intervention.
  • Text messaging: enable cost effective self-care.
  • Better patient outcomes: improves quality of life, reduces anxiety and increases confidence.
Current and planned activity: 
The SMC solution is deployed across multiple CCG’s and provider in the UK with over 10,000 patients benefiting from the system over the past 5 years. We have supported different operational and clinical pathways, including effective system deployment into patient homes and Care Home environments that can then enable pro-active and pre-emptive alerts to be raised with a Clinical care team.   Our technology and services have also been selected by a wide range of organisations including BT Health, Alere, Welch Allyn, MSD Commercial, Healthcare @Home to support new and existing service models in the field of telehealth.
We have long standing partnerships with Somerset CCG, Cornwall Foundation Trust Rotherham NHS Foundation Trust, and Dudley CCG and have been awarded innovator partnership on two Test Beds, one in Surrey and one in Manchester (with MSD Commercial.)

We support other conditions and pathways: Cystic Fibrosis, Falls and UTI, Spina Bifida children, LTC6 and E5QD quality of life.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Elisabeth Barbosa 12/01/2017 - 17:57 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
More people die of SUDEP (Sudden Unexpected Death in Epilepsy) than in house fires every year.
 
Every home has smoke detector, so why shouldn’t all epileptics have a device that alerts people close by so that they can provide assistance when needed?
Overview of Innovation:
Embrace is the world’s 1st system for seizure detection based on analysing multiple physiological data sensed at the wrist.



Should someone with Epilepsy experience an ‘unusual event’, such as a convulsive seizure, an alert will be sent via their smartphone to parents, friends or caregivers, summoning immediate help. Additionally, a caregiver can also wear a 'companion' Embrace. When the two Embraces are within range (e.g. in nearby rooms), the 'companion' Embrace worn by the caregivers will vibrate to alert them.

The Embrace watch has received awards for its design & innovative technology. The watch monitors Electrodermal Activity (EDA), also known as Galvanic Skin Response (GSR), which is autonomic data that is activated by regions deep in the brain involved in emotions such as fear, anxiety & excitement.
 
Embrace watch also functions as a sleep monitoring & activity tracking device.
 
What else do Embrace sensors monitor?
Embrace comes with an app called Mate. Mate combines events that are entered manually with events that are sensed by Embrace. Mate helps see how patterns of sleep, autonomic stress, skin temperature and physical activity may interact with seizure events. (NB: initial release of Mate app features rest and activity information, while features like autonomic stress monitoring, are still in development and will be added later). For example, if there are an increased number of absence seizures when stress levels have been high and sleep has been irregular, then these can be tracked to see if changing these patterns reduces the number of seizures.
 
Embrace and Alert app system for seizure detection is for investigational use only. The system is currently not clinically proven to detect seizures. Evidence of seizure characterization using the technology in Embrace has been gathered in a number of clinical trials since the initial discovery of skin conductance changes during a seizure was published in 2012. Empatica is currently conducting clinical trials to evaluate seizure detection of generalised tonic clonic seizures (GTCS) using the Embrace watch & Empatica Alert app.
 
The automatic physiological data logging provided by the Embrace system is valuable when someone experiences a seizure as they may not remember what has happened themselves. A diagnosis is often based on finding out what happened to the individual before, during and after a seizure.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The number of people in the UK diagnosed with epilepsy has risen sharply in recent years. There are around 65 million people living with epilepsy in the world, with an estimated 600,000 people in the UK.
 
Every day in the UK, 87 people are diagnosed with epilepsy. Only 52% people with epilepsy in the UK are seizure-free.
 
During 2013, 1,187 people in the UK with epilepsy died earlier than expected (premature death). Some of these deaths could have been prevented. A clinical audit of epilepsy deaths in 2002 found that 64 per cent of adult deaths and over half of child deaths were possibly or probably avoidable.
 
Epilepsy is misdiagnosed in 20-30% of cases: most commonly, non-epileptic conditions are incorrectly diagnosed as epilepsy. Up to 40% of children referred to a tertiary clinic do not have epilepsy.  In 2004, the National Institute for Clinical Excellence (NICE) estimated the direct costs of epilepsy misdiagnosis (including inappropriate treatment, but not including individuals’ lost productivity from misdiagnosis) to be between £130m and £190m per year (NICE (2004) Epilepsy, second consultation, Appendix G).
 
Limiting the rate of misdiagnosis will help to reduce the risk of teratogenicity in wrongly diagnosed patients and will prevent patients wrongly diagnosed with epilepsy from facing, for example, unnecessary restrictions in employment and in other areas of life. Better diagnostic services are also likely to reduce any treatment gaps or inequalities, and, through encouraging independent living, improve the rate of employability for people with epilepsy. Finally, patients will have a greater choice of treatment options and a greater sense of empowerment
 
Epilepsy is an ambulatory-sensitive condition, meaning that better management in the community or primary care setting can effectively avoid unnecessary visits to the emergency department and non-elective hospital admissions.
 
Prevention of 15 admissions to hospital would Save the salary of a single epilepsy nurse
Estimate from National Audit of Seizure Management in Hospitals 2 (NASH2)
 
In 2009, there were 13 million prescription items of anti-epileptic drugs dispensed in the community in England, at a net ingredient cost of £300 million (NHS Information Centre Prescription Cost Analysis 2009. The net ingredient cost is the cost of the drug before discounts, not including any dispensing costs of fees).
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Epilepsy affects 54,000 people in the West Midlands (Source Birmingham City Council May 2016). The economic and social costs of managing this cohort is very significant.
 
Gaining control of one’s epilepsy not only saves direct health related costs in terms of fewer emergency or longer term hospital admissions, but also enables individuals with epilepsy to continue working and maintain their independence.
Current and planned activity: 
Current activity:
The Embrace device was only recently launched in the UK in November 2016. Currently clinical trials are taking place in the USA.
https://support.empatica.com/hc/en-us/sections/200817625-Seizure-Characterization-Clinical-Trial-monitoring-with-Embrace
 
We have taken orders from a number of Local Authority Assistive technology departments and are keen to engage further with the NHS.

Planned/future activity:
The published trial results cited above were from predicate devices. We need to collect more data using the Embrace and Alert app to complete the medical and FDA certification processes before we are able to make any claims regarding seizure detection performance of this system.
 
We are very keen to work more closely with any West Midlands network that provides support to people with Epilepsy or Autism.
 
What is the intellectual property status of your innovation?:
Patents Held by Empatica – further info available upon request.

The device is currently being fast tracked through FDA approval.

It also holds - Certifications:  CE Mark, FCC CFR 47 Part 15,  RoHS.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Ben Carter 19/12/2016 - 13:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A functional, digital, patient-centric, diabetes self-test system providing: self-care; patient-professional shared decisions; proactive interventions; complications prevention; data integration pan NHS provider; multi-faceted NHS costs savings.
Overview of Innovation:
awergq3wrg3w
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
wefefgvw
Benefit to WM population:
f23ef2e
Current and planned activity: 
23rwefw
What is the intellectual property status of your innovation?:
fwergq3r5g
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Baldev 31/10/2016 - 14:26 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
BVI technology is an innovative and easy to use, mHealth service to determine the percentage and distribution of visceral fat using a mobile device (tablet) or a smart phone. 
Overview of Innovation:
The Body Volume Indicator (BVI) is a new measurement for healthcare and obesity. After eight years of successful and innovative validation from scientific collaborators around the world, BVI is now undergoing final testing prior to a full launch later in 2017.

Using 3D technology, BVI calculates risk factors associated with a person's body shape, by measuring weight and body fat distribution, with particular focus on the abdomen; the area associated with the greatest risk.

BVI is designed to be a long-term addition to the Body Mass Index (BMI); the current recognised standard for measurement of obesity. The intention is for the Body Volume Indicator to become a Body Volume Index by 2020, by which time sufficient data will have been collected globally. Using smartphone technology, BVI data can now be collected anywhere with web or internet access.

Body Volume, as an indicator of health, offers a potential long-term solution as a measure of individual health risk. 

BVI was developed in the West Midlands and collaborators have included Heartlands Hospital, Aston University, Mayo Clinic and the Medical Research Council. The application was patented in the US in 2012 and throughout Europe in 2015.


 
Current Status
In 2012 Select Research obtained exclusive use of the largest and most comprehensive collection of Body Composition Data (BCD) of visceral fat data from MRI scans in the world. This has been used to develop an App which will be used to scan/photograph lightly clothed patients and then comparing their BCD database to predict their body fat and visceral fat.
 
Further research and development is being undertaken with our current BVI (Body Volume Index) tool, to provide additional evidence and to validate the efficacy, and appropriateness of this BVI application in real-life environments. Through a ‘real-life’ project work with WMAHSN will provide clinical validation for the underpinning methodology, thus making potential users (Clinicians, patients & public) aware of the benefits (social and economic) of utilising the service.
 
Thus our current BVI application is to be incorporated into the existing patient pathways currently used by Health Exchange Health Trainers in the West Midlands.
 
NB: The application has been patented in the US in 2012 and throughout Europe in 2015 and covers all measurements of part body volume for healthcare from a 3D scan. Body fat is a part volume of the human body.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Visceral fat is body fat stored within the abdominal cavity around a number of important internal organs such as the liver, pancreas, and intestines often referred to as 'active fat'. This type of fat plays a potentially dangerous role in affecting how our hormones function.

Higher amounts of visceral fat are associated with increased risks of a number of health problems.  NHS healthcare costs attributed to obesity are £5.1b p.a. and set to rise by £7.1b by 2030; The cost to the UK economy is £27b p.a. Benefits through effective intervention based on accurate visceral body fat determinations are complex but undoubtedly would lead to a reduction in the burden of obesity (diabetes, heart disease, stroke, and certain cancers), by a reduction in years lost to premature mortality and disability (DALY). NICE suggests reducing obesity of 1% would save the “NHS and local authorities around £97 million per year.” Diabetes costs the NHS over £1.5m an hour or 10% of the NHS budget for England and Wales. 

The lifetime benefits of weight loss - direct £297 and indirect £2068 estimates based on 50% compliance and 25% success.  A saving to the NHS of between £1.2m and £6.9m, and the economy of between £135m and £1620m.

Select’s BVI tool App predicts the early identification body and visceral fat & estimates via a quick, simple and non-invasive scan which provides an insight and benchmark for clinicians and their patients; just by taking two photographs of a patient. 

Therefore BVI significantly contributes to the monitoring, intervention and control processes for clinicians and other health professional to apply, so that they can tackle and halt the potential for escalation into Diabetes and CHD etc.


Particular value for patients will be that they can monitor their own progress and to improvement at home. Through recognition of the scale of their own obesity and particularly any high levels of visceral fat. The early identification of visceral fat, through this simple, quick and accurate method of measuring obesity will thus take a large step towards achieving considerable saving to the NHS and the UK economy.

The proposal for delivery of BVI is under discussion with BVI data (including BMI, Waist Circumference, and Waist to Hip Ratio automatically) stored for tracking purposes on patient records via the N3 spine. Automatic data collection through BVI of current methods saves time, money and provides new informative data on body composition for future research.
Online Discussion Rating
5.50 (2 ratings)
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Clinical Outcomes & Economic
In the West Midlands 65.7 per cent of people are carrying excess weight, along with 65.6 per cent of people in the East Midlands. Obesity costs the UK economy exceed £3 billion per year. In Birmingham, over 25% of the population are obese - the third highest rate in the UK. The high prevalence of obesity in adults within England show that national averages of over 40% of males overweight and more than 20% obese in the 16-75 year age range, while in women the averages are lower for the overweight classification but higher for obesity.
 
Nationally GPs make 97,000 annual referrals to weight watching programmes (WWP) and costs will reach £15.6m p.a. in 2017. A saving of £48.5 per patient might be made using the BVI App. With as low as 10% uptake, £0.5m could be saved, rising to £2.8m with a 60% uptake. Better management of weight issues with patients will have significant cost savings within the West Midlands.
 
This tool will support early detection of visceral fat and therefore allow a much more preventative and timely approach to supporting West Midlands Patients to make positive lifestyle change.
 
Environmental
The BVI App offers considerable environmental benefits in reducing the number of visits (road trips) to a surgery and specialist clinics. It will also allow people within remote and rural locations to engage in such activities.
 
Research
Additional R&D is being undertaken with the WMAHSN, to further ‘validate’ the efficacy, appropriateness and validity of the BVI application in real-life environments using the BVI App, which is being incorporated into the existing patient pathways.
 
Commercially
The adoption of this technology within the West Midlands and UK will also allow our company to grow and develop, not only with increasing its functions and capabilities but also in marketing this to a worldwide healthcare organisations and individuals as obesity is a major developed countries epidemic. 
 
There is also interest from other commercial organisations involved in weight management and associated healthcare which will further extent this products role and integration with people taking charge of their well being.

Trials
The BVI tool will be tested in 3 locations in the West Midlands with patients and GP Practices in Birmingham, Dudley and Solihull. Analysis of weight loss achieved over a period will be monitored.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Current and planned activity: 
Current BVI application is undergoing R&D and incorporation into existing patient pathways within the West Midlands via;
  • Patient Engagement - Face to face consultation, scanning of approximately 1000+ patients
  • Clinical Benefits - Analysis and monitoring of weight loss achieved over a defined period. Developing delivery protocols
  • Dissemination - Facilitation of BVI tool awareness raising sessions with Key Public Health and NHS Management, Clinical Teams and frontline staff
  • Training - BVI tool training to specialist clinical teams (Primary & Acute), ensuring correct use of the tool and providing feedback for use with patients
  • Data analysis – Verification/validation of App algorithms
  • Data gathering - Provision of clinically requested data – Core data profiling to gauge health outcomes and patient benefits. Establishing minimum data requirements
Required
  • Evaluation & Trials - Seeking trial interests
  • Adoption – Looking for discussions with CCG’s, Healthcare and Council Health Prevention teams   
What is the intellectual property status of your innovation?:
BVI has both BVI Patents and Trademarks approved.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
We have not as yet implemented at scale within the WM region or elsewhere. The BVI product will be launched in the US market in March 2017 and Select Research Ltd are currently in discussions with Health Exchange and NHS Heartlands Hospital (who are collaborators on BVI development) for a possible follow on wider trial across the region for 2017.
Measures:
When the BVI app has been fully completed in terms of it’s scalability for widespread use, the trial results have been published and the launch takes place in April 2017, the success criteria will be determined by the number of users and the take up when the product is available and being used by customers.
 
Development is currently ongoing with scaling of the technical infrastructure for release on all accepted and recognised technical platforms (e.g. Google Play. App Store) in late April 2017. The success criteria will then become easily measurable by virtue of the volume of downloads achieved after launch.
Adoption target:
These will be dependent upon the outcome of the discussions with NHS Heartlands Hospital and Health Exchange as to a future extended trial.
Read more
Hide details
Richard Barnes 16/08/2016 - 13:59 Approved Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Lilie EPR captures outpatient activity, diagnoses and treatments for GUM patients, provides the team shared access to patient records enabling instant communication between the service, lab and patient; reducing costs with efficient data management.
Overview of Innovation:
Leading the way  in the Management of Sexual Health Services
The modern day sexual health service challenges are significant. Public Health England (PHE) indicate that there were 446,253 sexually transmitted infections diagnosed in England in 2013 with Chlamydia being the most common, making up 47 per cent of all diagnosed cases. The most expensive cost to the NHS is HIV Infection, each new case of HIV infection is estimated to represent between £280,000 & £360,000 in lifetime treatment costs. Although the fall in teenage pregnancy is one of the success stories of the last decade in the public health field. However there is always room for improvement especially with more sexually active young people.
 
Lilie provides Sexual Health clinics and HIV services with a comprehensive Sexual Health computer software solution. Lilie is a fully scalable Electronic Patient Record system (EPR) used to capture outpatient activity, referrals, diagnoses and treatments for genitourinary medicine (GUM) patients. Having all the patients’ data in one EPR system provides all the clinic team members with fast access to patient data greatly reducing administration functions. All audit and quality measures are incorporated automatically reducing clinical risks and improving the quality of sexual health services.

Lilie’s core is the base application which is a totally secure full EPR system with comprehensive patient communication, statutory reporting i.e. HARS, SRHAD and GUMCAD, adhoc report generation. Additional modules to the core system can be purchased allowing the client to meet their budgetary requirements. Additional modules include: Contraceptive & Reproductive Health which is a secure and efficient way to manage Contraceptive and Reproductive Health data and services/ Chlamydia Screening providing exceptional NCSP data capture and reporting facilities/ Prescribing which includes the Dictionary of Medicines and Devices (DM+D)/ SMS Texting is an effective way to improve patient communications and reduce DNA rates/ Touchscreen allows the patient to announce their arrival in clinic and discretely enter personal data/ Internet Booking to empower your patients with time-saving, secure appointment management/ Lab Communications for fast and secure ways to order laboratory tests and receive results/ Collect for collecting patient data using mobile devices within an outreach environment.


For more information visit http://6pmsolutions.com/products/clinical/lilie
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Improves Productivity
Lilie is intuitive and easy to use allowing clinicians to spend more quality time with patients whilst allowing clinics to reduce appointment, management and reporting times. By default, the patients’ previous responses to questions are automatically populated hence saving clinic time and improving patient care.

Speeds up data collection.
The patient data you collect during your general working day is input into the electronic patient record (EPR) easily. The software and the dynamic screens change, validate and evolve as you enter this data.   

Reduces DNA’s
Lilie Online Internet Booking offers patients a discreet, more convenient and alternative route to treatment without staff intervention reduces management costs.  Lilie discrete SMS Text messaging will send out appointment reminders giving the patient the ability to confirm or cancel an appointment, freeing up slots for other patients.


Ensures clinical safety and maximises patient convenience.  
Lilie displays a patient banner across the top of the screen displaying key patient information, ensuring clinical safety whilst speeding up the clinic consultation.

Intuitive and easy to use. 
Lilie allows clinics to be more flexible according to their own services requirements. The consultation screens are easy to use and patient data can be easily collected. Lilie is so intuitive, you will reduce your training needs.

Ensures accurate recording of data. 
Data is input during the consultation whilst ensuring the right questions are asked at the right time, reducing and removing transcription errors. Thus written notes and illegible hand writing are a thing of the past.  

Accessible anywhere.
Lilie is available on a web based N3 platform and the cloud allowing access to different users over the Internet. This ensures improved availability, no costly client installations and access from any trust computer or device.

Simplified deployment, maintenance and painless upgrades.
The Lilie hosted solution can be deployed quickly and easily since no client terminal installation is required. Drastically reducing the initial investment in IT infrastructure.
The hosted solution ensures software updates and backups are carried out “behind the scenes”, reducing the costs associated with client installations and reducing the involvement of IT department resources.  This also means that when the number of users increase, no further investment in hardware, bandwidth or resources is required.
 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The Best outcomes for people and for populations depend on effective collaboration and cooperation. We can get there faster with Lilie’s integrated working tools.

Nationally, around four million people per year use NHS contraception services. The number of visits to genito-urinary medicine (GUM) clinics has doubled over the last decade and now stands at over a million a year.  The economic climate and pressure on resources are encouraging everyone to explore new approaches and opportunities that can deliver better outcomes and better value. The fields of sexual health, sexually transmitted infection (STI), contraception, reproductive health and HIV are frequently talked about as a whole service, yet each is separate and has its own defining features. Different elements have different commissioning arrangements which add to the complexity.

Lilie EPR for sexual health has been designed specifically to support multi-disciplinary teams treating sexual health and HIV. This “whole system” approach makes sense to the service user, the community and the commissioner. Having patient data in an EPR system provides all clinic team members with fast access to patient records, greatly reducing administration functions. Unlike paper records, patient data can be accessed from any Trusts computer enabling more than one healthcare professional to access the same record at the same time.  Patients’ needs for integrated pathways are at the heart of the case for whole system commissioning. Poorly connected care increases the risk of service users falling out of the system which can reduce their treatment adherence and worsen subsequent health outcomes. Disjointed pathways also result in missed opportunities to address people’s wider needs.

‘Lilie is a complete comprehensive software system that manages; Sexual Health, Contraceptive, HIV and Reproductive Health services.  There is also a separate module for contraception, so as to provide ‘Services’ with a choice of modules depending on their requirements.’

Greater adoption of this technology would also allow our company to develop additional modules for this system, as well as expand our team here in the region.

Lilie is the market leading Sexual health software in the UK
Current and planned activity: 
Lilie is constantly being evaluated to ensure it meets the demands of the users.  The software roadmap is ever evolving and this is helped by the Lilie User groups where nearly 200 users attend annually.

A new version of Lilie is being released where dynamic forms will feature heavily.  For more information contact lilie@6pmplc.com.



Planned / required activity 
  • Procurement / Adoption: -  We would like to see greater regional adoption of our Lilie and integrated suites of products and modules
  • Trials - We are interested in discussing opportunities with Trusts for additional trials, evaluation and validation of our system 
What is the intellectual property status of your innovation?:
Lilie is owned by 6pm Group.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Joanne Shrimpton 16/06/2016 - 15:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':

Using simple technology, we enable care homes to coordinate the monitoring of vital signs, weight and hydration acting as an early warning system with direct integration into GP systems.

Overview of Innovation:

Inhealthcare have developed a Digital Care Home service, which coordinates the monitoring of vital signs, weight and hydration. It acts as an early warning system, highlighting changes in health which may otherwise go undetected. Their service includes a digital patient record which integrates directly with GP systems, meaning that it can be accessed by local NHS teams.

Our digital health services are in place in over 80 care homes in the UK, helping care home managers and nurses carry out frequent checks on residents.

Find out how it works on our website http://www.inhealthcare.co.uk/digital-health-solutions/care-homes/.

You can also read a blog from Georgia Nelson about a pilot of our Digital Care Home in 14 care homes in Northern Irealand http://www.inhealthcare.co.uk/telehealth-undernutrition-service-care-homes-northern-ireland/.

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
  1. Reduces non-elective admissions through detecting deteriorating health early on
  2. Improves co-ordination between the NHS and the care home through better sharing of information with GP system integration
  3. Supports early hospital discharge by giving clinicians more confidence that needs will be met in the care home
  4. Improves the visibility of residents’ health, meaning community nurses can better monitor patients without the need for travel
  5. Improves compliance around care
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:

1. Enhanced monitoring of residents, enabling early detection of health deterioration enabling timely intervention.

Current and planned activity: 

Our digital health services are in place in over 80 care homes in the UK, helping care home managers and nurses carry out frequent checks on residents.
 

Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Lauren Ramsey 24/05/2016 - 14:41 Publish Login or Register to post comments
3
1
Votes
-99999

Recent Activities

IoT solutions for Integrated Health and Social Care Technology has been moved from Initial Submission to Publish 2 weeks 5 days ago
Biobanking Management Software - MbioLIMS has been moved from Initial Submission to Publish 1 month 2 weeks ago
Amplitude ​pro enterprise has been moved from Initial Submission to Publish 1 month 3 weeks ago
Sonia Hussein commented on Sensium: Early Detection of Patient Deterioration. Seamless ambulatory vital sign monitoring for the general ward population. 2 months 16 hours ago
Sonia Hussein commented on Sensium: Early Detection of Patient Deterioration. Seamless ambulatory vital sign monitoring for the general ward population. 2 months 16 hours ago

Active Campaigns